Drug Trial Radar · NCT07063342
A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
236
Planned (sponsor's estimate)
Start
Jun 27, 2025
Primary completion
Mar 29, 2027
Study completion Mar 29, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate novel KarX and KarT prototypes versus the KarXT and KarX-EC reference following single doses, to explore the effect of food after multiple doses of selected prototypes, and to evaluate alternative formulations of KarX and KarXT following single and multiple ascending doses in healthy adult participants.
Conditions
- Healthy Volunteers
Interventions
Xanomeline/Trospium Chloride CapsuleDrug
Specified dose on specified days
Xanomeline Enteric CapsuleDrug
Specified dose on specified days
Trospium ChlorideDrug
Specified dose on specified days
Xanomeline MRDrug
Specified dose on specified days
XanomelineDrug
Specified dose on specified days
PlaceboDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed concentration (Cmax)Time frame: Up to Day 23
- Time of maximum observed concentration (Tmax)Time frame: Up to Day 23
- Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))Time frame: Up to Day 23
- Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))Time frame: Up to Day 23
- Area under the concentration-time curve in 1 dosing interval (AUC(TAU))Time frame: Up to Day 23
- Concentration at the end of a dosing interval (Ctau)Time frame: Up to Day 23
- Apparent total body clearance (CLT/F)Time frame: Up to Day 23
- Effective elimination half-life during dosing interval (T-HALF(eff))Time frame: Up to Day 23
- Number of participants with Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 30 days after final dose of study intervention
- Number of participants with Serious Adverse Events (SAEs)Time frame: Up to 30 days after final dose of study intervention
- Number of participants with Adverse Events of Special Interest (AESIs)Time frame: Up to 30 days after final dose of study intervention
- Number of participants with AEs leading to discontinuationTime frame: Up to 30 days after final dose of study intervention
- Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences
Nottingham, Nottinghamshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.